Literature DB >> 17846888

Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2.

Kaz Jaskiewicz1, Robert Rzepko, Zbigniew Sledzinski.   

Abstract

Fatty liver in obese patients is emerging as one of the most common causes of chronic liver disease. Obese patients are at risk of developing type 2 diabetes mellitus (DM), and aggravating non-alcoholic fatty liver disease (NAFLD), developing into steatohepatitis (NASH) and hepatic fibrosis. Little is known of the possible impact on liver fibrogenesis of diabetes type 2 associated with obesity and NAFLD. Fifty-two morbidly obese patients were evaluated with complete clinical and laboratory medical assessment. Liver biopsy material was fixed in formalin, routinely processed to paraffin blocks, cut into 4-microm sections, stained with HE, PAS, Masson's trichrome and reticulin. Immunohistochemical stains included collagen IV, SMA and laminin. Within the initial group of 52, 25 patients had DM type 2, mean age 45.8 years. Patients with diabetes were older; had higher BMI, liver enzyme tests, glucose, cholesterol, and triglycerides; and lower albumin concentration. Livers of diabetics had significantly more severe steatosis and rich perisinusoidal collagen IV, laminin and SMA accumulation without histologically detectable NASH and irrespective of the degree of steatosis. Obese patients with type 2 DM and insulin resistance develop more severe NAFLD and early sinusoidal fibrosclerosis.

Entities:  

Mesh:

Year:  2007        PMID: 17846888     DOI: 10.1007/s10620-007-9942-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

1.  Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease.

Authors:  G Targher; L Bertolini; R Padovani; F Poli; L Scala; R Tessari; L Zenari; G Falezza
Journal:  Diabet Med       Date:  2006-04       Impact factor: 4.359

2.  Diabetic hepatosclerosis: diabetic microangiopathy of the liver.

Authors:  Stephen A Harrison; Elizabeth M Brunt; Zachary D Goodman; Adrian M Di Bisceglie
Journal:  Arch Pathol Lab Med       Date:  2006-01       Impact factor: 5.534

3.  Nonalcoholic fatty liver disease treated by gastroplasty.

Authors:  K Jaskiewicz; S Raczynska; R Rzepko; Z Sledziński
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

4.  Pathology of nonalcoholic steatohepatitis.

Authors:  Elizabeth M Brunt
Journal:  Hepatol Res       Date:  2005-10-07       Impact factor: 4.288

5.  Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease.

Authors:  Ariel E Feldstein; Bettina G Papouchado; Paul Angulo; Schyler Sanderson; Leon Adams; Gregory J Gores
Journal:  Clin Gastroenterol Hepatol       Date:  2005-04       Impact factor: 11.382

6.  Hepatic steatosis and insulin resistance: does etiology make a difference?

Authors:  Amedeo Lonardo; Silvia Lombardini; Federica Scaglioni; Lucia Carulli; Matteo Ricchi; Dorval Ganazzi; Luigi Elio Adinolfi; Giuseppe Ruggiero; Nicola Carulli; Paola Loria
Journal:  J Hepatol       Date:  2005-07-12       Impact factor: 25.083

Review 7.  Non alcoholic fatty liver disease: a clinical approach and review.

Authors:  Maitreyi Raman; Johanne Allard
Journal:  Can J Gastroenterol       Date:  2006-05       Impact factor: 3.522

8.  Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.

Authors:  Elizabeth M Brunt; Brent A Neuschwander-Tetri; Dana Oliver; Kent R Wehmeier; Bruce R Bacon
Journal:  Hum Pathol       Date:  2004-09       Impact factor: 3.466

9.  Nonalcoholic fatty liver disease in patients with type 2 diabetes.

Authors:  Zobair M Younossi; Terry Gramlich; Christi A Matteoni; Navdeep Boparai; Arthur J McCullough
Journal:  Clin Gastroenterol Hepatol       Date:  2004-03       Impact factor: 11.382

10.  Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration.

Authors:  Giovanni Davì; Francesco Chiarelli; Francesca Santilli; Mariapina Pomilio; Sergio Vigneri; Angela Falco; Stefania Basili; Giovanni Ciabattoni; Carlo Patrono
Journal:  Circulation       Date:  2003-06-16       Impact factor: 29.690

View more
  12 in total

1.  In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis.

Authors:  Jonathan A Africa; Cynthia A Behling; Elizabeth M Brunt; Nan Zhang; Yunjun Luo; Alan Wells; Jiayi Hou; Patricia H Belt; Rohit Kohil; Joel E Lavine; Jean P Molleston; Kimberly P Newton; Peter F Whitington; Jeffrey B Schwimmer
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-07       Impact factor: 11.382

Review 2.  The extracellular matrix and insulin resistance.

Authors:  Ashley S Williams; Li Kang; David H Wasserman
Journal:  Trends Endocrinol Metab       Date:  2015-06-06       Impact factor: 12.015

3.  Integrin α1-null mice exhibit improved fatty liver when fed a high fat diet despite severe hepatic insulin resistance.

Authors:  Ashley S Williams; Li Kang; Jenny Zheng; Carrie Grueter; Deanna P Bracy; Freyja D James; Ambra Pozzi; David H Wasserman
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

4.  Obesity, type 2 diabetes, age, and female gender: significant risk factors in the development of alcoholic liver cirrhosis.

Authors:  Yoshinori Horie; Yoshiyuki Yamagishi; Hirotoshi Ebinuma; Toshifumi Hibi
Journal:  Hepatol Int       Date:  2012-02-09       Impact factor: 6.047

5.  Steatosis and steatohepatitis in postmortem material from Northwestern Greece.

Authors:  Christos-D Zois; Gerasimos-H Baltayiannis; Anna Bekiari; Anna Goussia; Peter Karayiannis; Michalis Doukas; Demetrios Demopoulos; Antigoni Mitsellou; Theodoros Vougiouklakis; Vasiliki Mitsi; Epameinondas-V Tsianos
Journal:  World J Gastroenterol       Date:  2010-08-21       Impact factor: 5.742

6.  Risk factors and mechanisms of non-alcoholic steatohepatitis.

Authors:  Chantal A Rivera
Journal:  Pathophysiology       Date:  2008-07-29

7.  Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients.

Authors:  Michelle DallaPiazza; Valerianna K Amorosa; Russell Localio; Jay R Kostman; Vincent Lo Re
Journal:  BMC Infect Dis       Date:  2010-05-13       Impact factor: 3.090

Review 8.  Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages.

Authors:  Lucía Fuentes; Tamás Roszer; Mercedes Ricote
Journal:  Mediators Inflamm       Date:  2010-05-20       Impact factor: 4.711

9.  Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.

Authors:  Bharat K Puchakayala; Siddharth Verma; Pushpjeet Kanwar; John Hart; Raghavendra R Sanivarapu; Smruti R Mohanty
Journal:  World J Hepatol       Date:  2015-11-08

10.  Fructus Xanthii attenuates hepatic steatosis in rats fed on high-fat diet.

Authors:  Xiumin Li; Zhipeng Li; Mei Xue; Zhimin Ou; Ming Liu; Mingxing Yang; Suhuan Liu; Shuyu Yang; Xuejun Li
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.